Fig. 6: Repeated intravenous administration of hiPSC-MSCs improved the engraftment of transplanted hiPSC-MSCs in ischemic tissue. | Communications Biology

Fig. 6: Repeated intravenous administration of hiPSC-MSCs improved the engraftment of transplanted hiPSC-MSCs in ischemic tissue.

From: Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration

Fig. 6

The engraftment of intramuscularly transplanted hiPSC-MSCs was further confirmed by double immunohistochemical staining with anti-human GAPDH (green) and anti-human mitochondria antibodies (red) at day 14 and 35 (a). A single or repeated intravenous hiPSC-MSC infusion in the MSC-MSC/once, MSC-MSC/week and MSC-MSC/3 days groups significantly improved the engraftment of intramuscularly transplanted hiPSC-MSCs from day 14 onwards (all p < 0.05). Repeated intravenous hiPSC-MSC infusion in the MSC-MSC/week and MSC-MSC/3 days groups further improved the engraftment of intramuscular transplanted hiPSC-MSCs at day 35 compared with the MSC-MSC/once group (all p < 0.05), whereas no significant difference was observed between the MSC-MSC/week and MSC-MSC/3 days groups (p > 0.05) (b).

Back to article page